NeoGenomics Secures Medicare Coverage for Immunotherapy Monitoring with RaDaR ST Assay
Event summary
- NeoGenomics' RaDaR ST assay received expanded Medicare coverage for immunotherapy monitoring in late-stage solid tumors.
- This is the third Medicare-covered indication for RaDaR ST, following approvals for HPV-negative head and neck cancer and a subset of HR+, HER2-negative breast cancer.
- RaDaR ST employs a tumor-informed approach, analyzing up to 48 patient-specific variants to detect circulating tumor DNA (ctDNA).
- NeoGenomics has two additional RaDaR ST submissions pending with MolDX.
The big picture
NeoGenomics' expanded Medicare coverage for RaDaR ST underscores the growing importance of molecular diagnostics in immunotherapy. As immunotherapy becomes standard treatment for numerous solid tumors, tools like RaDaR ST that provide longitudinal molecular insights are becoming critical for treatment decisions. This coverage marks a significant milestone in expanding access to RaDaR ST in a large and growing indication, potentially reshaping how clinicians monitor treatment response in late-stage solid tumors.
What we're watching
- Market Expansion
- How NeoGenomics will leverage this coverage to expand RaDaR ST's market reach in immunotherapy monitoring.
- Reimbursement Dynamics
- Whether the additional Medicare coverage will accelerate physician adoption and reimbursement for RaDaR ST.
- Competitive Positioning
- The pace at which NeoGenomics can secure further reimbursement decisions to support growth.
Related topics